Tango Therapeutics (TNGX) Change in Accured Expenses (2020 - 2026)

Tango Therapeutics' Change in Accured Expenses history runs 7 years deep, the most recent figure standing at -$8.7 million for Q1 2026.

• On a quarterly basis, Change in Accured Expenses fell 41.9% year-over-year to -$8.7 million in Q1 2026; TTM through Mar 2026 was -$1.5 million, a 56.76% increase from a year earlier, with the FY2025 full-year figure at $1.1 million, down 2.65% from the prior year.
• Change in Accured Expenses fell to -$8.7 million in Q1 2026 per TNGX's latest filing, from $4.5 million in the prior quarter.
• Across five years, Change in Accured Expenses topped out at $4.5 million in Q4 2025 and bottomed at -$8.7 million in Q1 2026.
• The 5-year median for Change in Accured Expenses is $1.5 million (2024), against an average of -$50117.6.
• Across the five-year window, Change in Accured Expenses surged 4985.71% in 2022 and slumped 4169.43% in 2023, its largest moves.
• Year by year, Change in Accured Expenses stood at $1.8 million in 2022, then soared by 124.55% to $4.0 million in 2023, then sank by 62.7% to $1.5 million in 2024, then surged by 201.01% to $4.5 million in 2025, then plunged by 293.63% to -$8.7 million in 2026.
• Per Business Quant, the three latest TNGX Change in Accured Expenses figures stand at -$8.7 million (Q1 2026), $4.5 million (Q4 2025), and $1.6 million (Q3 2025).